IQVIA Biotech

Jan 13, 2025 | lifesciencesbc.ca | IQVIA Biotech

Member NewsJanuary 13, 2025IQVIA BiotechRESEARCH TRIANGLE PARK, NC – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions.

Oct 29, 2024 | clinicalleader.com | Kristel Rens |Matt Simmons |IQVIA Biotech

Webinar: Unleash the Power of IQVIA Complete ConsentThe eConsent market is evolving, focusing on improving patient experiences, streamlining clinical trial processes, and global expansion. Staying informed on industry developments is crucial.

Sep 18, 2024 | clinicalleader.com | Jimmy Bechtel |Stacie Bell |Erin Finot |IQVIA Biotech

Remote Services And Technology Require More Regulatory Clarity For InvestigatorsBy focusing on updating regulatory frameworks, developing technical standards, and leveraging technology for compliance, see how the industry can ensure that digital and remote trials are conducted safely and ethically. Can Optimized Cardiology Trials Solve Major Challenges?

Aug 22, 2024 | clinicalleader.com | Erin Finot |IQVIA Biotech

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell and Gene Therapy, IQVIA Biotech Designing clinical trials for immuno-oncology (IO) therapies, particularly those involving cell- and gene-based treatments, presents unique scientific and operational challenges. To navigate these complexities, biotech and emerging biopharma companies must adopt strategic approaches tailored to key regulatory and logistical hurdles.

Jul 2, 2024 | clinicalleader.com | Erin Finot |IQVIA Biotech

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell and Gene Therapy, IQVIA Biotech Gene therapy has surged in the clinical research industry, marked by significant growth and interest. In 2023, venture capital funding reached $3.4 billion, with 406 industry-sponsored clinical trials initiated and 76 cell and gene therapies launched globally.